SAB 176
Alternative Names: Anti-influenza human immunoglobulin - SAB BIO; SAB-176Latest Information Update: 25 Jun 2024
Price :
$50 *
At a glance
- Originator SAB Biotherapeutics
- Developer SAB BIO
- Class Antivirals; Immunoglobulins
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Influenza A virus H1N1 subtype
- Phase I Influenza A virus infections; Influenza B virus infections